Severity
Moderate
FDA Drug recall · Reported June 8, 2016
Marketed Without An Approved NDA/ANDA: Contains an unapproved drug, ligandrol LGD-4033
Invisiblu International LLC recalled LGD-Xtreme (ligandrol LGD-4033),capsules, 3 mg, 90-count bottle, Manufactured for Contin… - a moderate-severity action.
LGD-Xtreme (ligandrol LGD-4033),capsules, 3 mg, 90-count bottle, Manufactured for Contin… was recalled by Invisiblu International LLC in June 8, 2016. Reason: Marketed Without An Approved NDA/ANDA: Contains an unapproved drug, ligandrol LGD-4033. Check the official notice for the remedy. Verify recall #D-0910-2016 with the FDA Drug before acting.
The recall
Invisiblu International LLC issued this moderate-severity FDA Drug recall-Marketed Without An Approved NDA/ANDA: Contains an unapproved drug, ligandrol LGD-4033.
Sourced from official FDA Drug enforcement records. Verify recall #D-0910-2016 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0910-2016) was formally reported on June 8, 2016, with the manufacturer initiating the action on March 31, 2016. It is classified under Moderate severity (Class II), with a current status of Ongoing. Invisiblu International LLC is listed as the recalling firm, operating out of Fort Lauderdale, FL. Federal records list the affected scope as 3,319 bottles.
The documented reason for this recall is: Marketed Without An Approved NDA/ANDA: Contains an unapproved drug, ligandrol LGD-4033 Distribution data in the federal record shows the product reached: Nationwide and Brazil.. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
3,319 bottles
Related Recalls
6
5 from same agency
LGD-Xtreme (ligandrol LGD-4033),capsules, 3 mg, 90-count bottle, Manufactured for Continuum Labs, Fort Lauderdale, FL
Marketed Without An Approved NDA/ANDA: Contains an unapproved drug, ligandrol LGD-4033
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Ongoing |
| Recall number | D-0910-2016 |
| Date reported | June 8, 2016 |
| Date initiated | March 31, 2016 |
| Recalling firm | Invisiblu International LLC |
| Firm location | Fort Lauderdale, FL |
| Affected scope | 3,319 bottles |
| Distribution | Nationwide and Brazil. |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported June 8, 2016. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.